Brief: Exicure Granted Orphan Drug Designation By U.S. Food And Drug Administration For Cavrotolimod
03/03/2021 12:08
March 3 (Reuters) - Exicure Inc XCUR.O :
* EXICURE GRANTED ORPHAN DRUG DESIGNATION BY THE U.S. FOOD
AND
DRUG ADMINISTRATION FOR CAVROTOLIMOD
Source text for Eikon: ID:nBw31nQ51a
Further company coverage: XCUR.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Exicure
See all newsBrief: Exicure Announces 1-For-5 Reverse Stock Split
U.S. STOCKS ON THE MOVE-MercadoLibre, DoorDash, Coinbase
Brief: Exicure Inc Says Received Nasdaq Delinquency Notice On Late Filing Of Its Form 10-K
Brief: Exicure And Bluejay Therapeutics Enter Into A Patent License Agreement To Develop Cavrotolimod For The Treatment Of Hepatitis
Brief: Exicure Says Co Received Notice Of Delisting Or Failure To Satisfy A Continued Listing Rule Or Standard From Nasdaq